Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/10474
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Çakmak, E. | en_US |
dc.contributor.author | Sarı, Hakan İsmail | en_US |
dc.contributor.author | Canoz, Ö. | en_US |
dc.contributor.author | Eser, B. | en_US |
dc.contributor.author | Altuntaş, F. | en_US |
dc.contributor.author | Çetin, M. | en_US |
dc.contributor.author | Ünal, A. | en_US |
dc.date.accessioned | 2019-08-16T13:19:11Z | - |
dc.date.available | 2019-08-16T13:19:11Z | - |
dc.identifier.issn | 1300-199X | - |
dc.identifier.uri | https://hdl.handle.net/11499/10474 | - |
dc.identifier.uri | https://doi.org/10.5152/etd.2015.150001 | - |
dc.description.abstract | Objective: P53, Bcl-2, and Fas proteins play significant roles in lymphoid cell apoptosis. These proteins affect the prognosis and treatment response of lymphoma and various malignancies. The aim of the present study was to investigate the effects of P53, Bcl-2, and Fas protein expression on treatment and prognosis in patients with primary gastrointestinal diffuse large B-cell lymphoma. Materials and Methods: Thirty-nine patients with primary gastrointestinal diffuse large B-cell lymphoma were included in the study. Immunohistochemical staining was performed to analyze P53, Bcl-2, and Fas protein expression levels in paraffin sections. Results: We examined 39 patients with primary gastrointestinal diffuse large B-cell lymphoma, 21 males and 18 females, with a median age of 54 years. P53 protein expression was detected in 24 patients (61.5%), Bcl-2 protein expression was detected in 26 (67%), and Fas protein expression was detected in 28 (72%). The five-year overall survival rate was significantly lower in patients with P53 and Bcl-2 expression; on the other hand, we did not find a significant difference in the five-year overall survival with respect to Fas protein expression. Conclusion: We found that P53 and Bcl-2 protein expression had a negative effect on prognosis and survival in patients with primary gastrointestinal diffuse large B-cell lymphoma. However, Fas protein expression had no effect on prognosis and survival. Taken together, patients with P53 and Bcl-2 expression should be considered to have a high risk from the beginning, and these patients should undergo aggressive treatments. © 2015 by Erciyes University School of Medicine. | en_US |
dc.language.iso | en | en_US |
dc.publisher | AVES Ibrahim Kara | en_US |
dc.relation.ispartof | Erciyes Tip Dergisi | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Bcl-2 | en_US |
dc.subject | Fas | en_US |
dc.subject | Lymphoma | en_US |
dc.subject | P53 | en_US |
dc.subject | Prognosis | en_US |
dc.subject | biological marker | en_US |
dc.subject | bleomycin | en_US |
dc.subject | cisplatin | en_US |
dc.subject | cyclophosphamide | en_US |
dc.subject | cytarabine | en_US |
dc.subject | dexamethasone | en_US |
dc.subject | doxorubicin | en_US |
dc.subject | etoposide | en_US |
dc.subject | Fas antigen | en_US |
dc.subject | folinic acid | en_US |
dc.subject | methotrexate | en_US |
dc.subject | methylprednisolone | en_US |
dc.subject | prednisolone | en_US |
dc.subject | protein bcl 2 | en_US |
dc.subject | protein p53 | en_US |
dc.subject | vincristine | en_US |
dc.subject | adult | en_US |
dc.subject | aged | en_US |
dc.subject | Article | en_US |
dc.subject | cancer chemotherapy | en_US |
dc.subject | cancer prognosis | en_US |
dc.subject | clinical article | en_US |
dc.subject | electrocorticography | en_US |
dc.subject | female | en_US |
dc.subject | gastrointestinal disease | en_US |
dc.subject | human | en_US |
dc.subject | immunohistochemistry | en_US |
dc.subject | International Prognostic Index | en_US |
dc.subject | lactate dehydrogenase blood level | en_US |
dc.subject | large cell lymphoma | en_US |
dc.subject | male | en_US |
dc.subject | middle aged | en_US |
dc.subject | overall survival | en_US |
dc.subject | protein expression | en_US |
dc.subject | retrospective study | en_US |
dc.subject | treatment response | en_US |
dc.title | Prognostic significance of P53, Bcl-2, and fas expression in patients with primary gastrointestinal diffuse large B-cell lymphoma | en_US |
dc.type | Article | en_US |
dc.identifier.volume | 37 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.startpage | 102 | en_US |
dc.identifier.endpage | 105 | en_US |
dc.identifier.doi | 10.5152/etd.2015.150001 | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.scopus | 2-s2.0-84944735471 | - |
dc.identifier.trdizinid | 230323 | en_US |
dc.identifier.wos | WOS:000364023200004 | en_US |
dc.identifier.scopusquality | Q4 | - |
dc.owner | Pamukkale University | - |
item.fulltext | With Fulltext | - |
item.languageiso639-1 | en | - |
item.openairetype | Article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | open | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
Appears in Collections: | Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
document (1).pdf | 121.65 kB | Adobe PDF | View/Open |
CORE Recommender
SCOPUSTM
Citations
1
checked on Nov 16, 2024
Page view(s)
88
checked on Aug 24, 2024
Download(s)
20
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.